Skip to main content
Erschienen in:

18.08.2016 | Original Article

Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency

verfasst von: Tami John, Jolan E. Walter, Catherina Schuetz, Karin Chen, Roshini S. Abraham, Carmem Bonfim, Thomas G. Boyce, Avni Y. Joshi, Elizabeth Kang, Beatriz Tavares Costa Carvalho, Arash Mahajerin, Diane Nugent, Geetha Puthenveetil, Amit Soni, Helen Su, Morton J. Cowan, Luigi Notarangelo, David Buchbinder

Erschienen in: Journal of Clinical Immunology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The use of HLA-identical hematopoietic stem cell transplantation (HSCT) demonstrates overall survival rates greater than 75 % for T-B-NK+ severe combined immunodeficiency secondary to pathogenic mutation of recombinase activating genes 1 and 2 (RAG1/2). Limited data exist regarding the use of HSCT in patients with hypomorphic RAG variants marked by greater preservation of RAG activity and associated phenotypes such as granulomatous disease in combination with autoimmunity. We describe a 17-year-old with combined immunodeficiency and immune dysregulation characterized by granulomatous lung disease and autoimmunity secondary to compound heterozygous RAG mutations. A myeloablative reduced toxicity HSCT was completed using an unrelated bone marrow donor. With the increasing cases of immune dysregulation being discovered with hypomorphic RAG variants, the use of HSCT may advance to the forefront of treatment. This case serves to discuss indications of HSCT, approaches to preparative therapy, and the potential complications in this growing cohort of patients with immune dysregulation and RAG deficiency.
Literatur
1.
Zurück zum Zitat Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38.CrossRefPubMedPubMedCentral Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–55.CrossRefPubMed Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–55.CrossRefPubMed
3.
Zurück zum Zitat Dvorak CC, Hassan A, Slatter MA, Honig M, Lankester AC, Buckley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134(4):935–43. e15.CrossRefPubMedPubMedCentral Dvorak CC, Hassan A, Slatter MA, Honig M, Lankester AC, Buckley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134(4):935–43. e15.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015;125(11):4135–48.CrossRefPubMedPubMedCentral Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015;125(11):4135–48.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Buchbinder D, Baker R, Lee YN, Ravell J, Zhang Y, McElwee J, et al. Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders. J Clin Immunol. 2015;35(2):119–24.CrossRefPubMed Buchbinder D, Baker R, Lee YN, Ravell J, Zhang Y, McElwee J, et al. Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders. J Clin Immunol. 2015;35(2):119–24.CrossRefPubMed
6.
Zurück zum Zitat Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358(19):2030–8.CrossRefPubMed Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358(19):2030–8.CrossRefPubMed
7.
Zurück zum Zitat Reiff A, Bassuk AG, Church JA, Campbell E, Bing X, Ferguson PJ. Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. J Clin Immunol. 2013;33(8):1289–92.CrossRefPubMed Reiff A, Bassuk AG, Church JA, Campbell E, Bing X, Ferguson PJ. Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. J Clin Immunol. 2013;33(8):1289–92.CrossRefPubMed
8.
Zurück zum Zitat Geier CB, Piller A, Linder A, Sauerwein KM, Eibl MM, Wolf HM. Leaky RAG deficiency in adult patients with impaired antibody production against bacterial polysaccharide antigens. PLoS One. 2015;10(7), e0133220.CrossRefPubMedPubMedCentral Geier CB, Piller A, Linder A, Sauerwein KM, Eibl MM, Wolf HM. Leaky RAG deficiency in adult patients with impaired antibody production against bacterial polysaccharide antigens. PLoS One. 2015;10(7), e0133220.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Schuetz C, Pannicke U, Jacobsen EM, Burggraf S, Albert MH, Honig M, et al. Lesson from hypomorphic recombination-activating gene (RAG) mutations: why asymptomatic siblings should also be tested. J Allergy Clin Immunol. 2014;133(4):1211–5.CrossRefPubMed Schuetz C, Pannicke U, Jacobsen EM, Burggraf S, Albert MH, Honig M, et al. Lesson from hypomorphic recombination-activating gene (RAG) mutations: why asymptomatic siblings should also be tested. J Allergy Clin Immunol. 2014;133(4):1211–5.CrossRefPubMed
10.
Zurück zum Zitat Norarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016;16(4):234–46.CrossRef Norarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016;16(4):234–46.CrossRef
11.
Zurück zum Zitat Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014;133(3):880–2. e10.CrossRefPubMedPubMedCentral Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014;133(3):880–2. e10.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Avila EM, Uzel G, Hsu A, Milner JD, Turner ML, Pittaluga S, et al. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics. 2010;126(5):e1248–52.CrossRefPubMed Avila EM, Uzel G, Hsu A, Milner JD, Turner ML, Pittaluga S, et al. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics. 2010;126(5):e1248–52.CrossRefPubMed
13.
Zurück zum Zitat De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116(8):1263–71.CrossRefPubMedPubMedCentral De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116(8):1263–71.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Henderson LA, Frugoni F, Hopkins G, de Boer H, Pai SY, Lee YN, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132(4):969–71. e1-2.CrossRefPubMed Henderson LA, Frugoni F, Hopkins G, de Boer H, Pai SY, Lee YN, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132(4):969–71. e1-2.CrossRefPubMed
15.
Zurück zum Zitat Marrella V, Poliani PL, Notarangelo LD, Grassi F, Villa A. Rag defects and thymic stroma: lessons from animal models. Front Immunol. 2014;5:259.PubMedPubMedCentral Marrella V, Poliani PL, Notarangelo LD, Grassi F, Villa A. Rag defects and thymic stroma: lessons from animal models. Front Immunol. 2014;5:259.PubMedPubMedCentral
16.
Zurück zum Zitat Karo JM, Schatz DG, Sun JC. The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells. Cell. 2014;159(1):94–107.CrossRefPubMedPubMedCentral Karo JM, Schatz DG, Sun JC. The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells. Cell. 2014;159(1):94–107.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112(1):219–27.CrossRefPubMed Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112(1):219–27.CrossRefPubMed
18.
Zurück zum Zitat Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C, et al. Boost of CD34 + −selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91(7):935–40.PubMed Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C, et al. Boost of CD34 + −selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91(7):935–40.PubMed
19.
Zurück zum Zitat Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W. Poor graft function can be durably and safely improved by CD34 + −selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol. 2015;141(12):2241–51.CrossRefPubMed Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W. Poor graft function can be durably and safely improved by CD34 + −selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol. 2015;141(12):2241–51.CrossRefPubMed
20.
Zurück zum Zitat Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29(7):545–52.CrossRefPubMed Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29(7):545–52.CrossRefPubMed
21.
Zurück zum Zitat Lev A, Simon AJ, Bareket M, Bielorai B, Hutt D, Amariglio N, et al. The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients. PLoS One. 2012;7(1), e30494.CrossRefPubMedPubMedCentral Lev A, Simon AJ, Bareket M, Bielorai B, Hutt D, Amariglio N, et al. The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients. PLoS One. 2012;7(1), e30494.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Buckley RH, Win CM, Moser BK, Parrott RE, Sajaroff E, Sarzotti-Kelsoe M. Post-transplantation B cell function in different molecular types of SCID. J Clin Immunol. 2013;33(1):96–110.CrossRefPubMed Buckley RH, Win CM, Moser BK, Parrott RE, Sajaroff E, Sarzotti-Kelsoe M. Post-transplantation B cell function in different molecular types of SCID. J Clin Immunol. 2013;33(1):96–110.CrossRefPubMed
23.
Zurück zum Zitat Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123(2):281–9.CrossRefPubMedPubMedCentral Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123(2):281–9.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, et al. Treosulfan based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood 2016. Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, et al. Treosulfan based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood 2016.
25.
Zurück zum Zitat Slatter MA, Boztug H, Potschger U, Sykora KW, Lankester A, Yaniv I, et al. Treosulfan-based conditioning regimens for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50(12):1536–41.CrossRefPubMed Slatter MA, Boztug H, Potschger U, Sykora KW, Lankester A, Yaniv I, et al. Treosulfan-based conditioning regimens for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50(12):1536–41.CrossRefPubMed
26.
Zurück zum Zitat Slatter MA, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S, et al. Treosulfan-based conditioning regimens for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367–75.CrossRefPubMed Slatter MA, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S, et al. Treosulfan-based conditioning regimens for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367–75.CrossRefPubMed
Metadaten
Titel
Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency
verfasst von
Tami John
Jolan E. Walter
Catherina Schuetz
Karin Chen
Roshini S. Abraham
Carmem Bonfim
Thomas G. Boyce
Avni Y. Joshi
Elizabeth Kang
Beatriz Tavares Costa Carvalho
Arash Mahajerin
Diane Nugent
Geetha Puthenveetil
Amit Soni
Helen Su
Morton J. Cowan
Luigi Notarangelo
David Buchbinder
Publikationsdatum
18.08.2016
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 7/2016
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-016-0326-x

Weitere Artikel der Ausgabe 7/2016

Journal of Clinical Immunology 7/2016 Zur Ausgabe

Kompaktes Leitlinien-Wissen Innere Medizin

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Höheres ALL-Risiko unter Lenalidomid?

Daten aus randomisierten kontrollierten Studien und einer Pharmakovigilanzdatenbank legen nahe, dass eine Lenalidomid-haltige Therapie bei Myelomerkrankten das Risiko für eine akute lymphatische Leukämie erhöhen kann.

Antiemetische Therapie: Ein Tag Dexamethason genügt!

Wird Dexamethason zur antiemetischen Behandlung bei einer Krebschemotherapie benötigt, reicht in der Regel eine Anwendung am ersten Tag des Zyklus. Übelkeit und Erbrechen lassen sich damit ähnlich gut kontrollieren wie mit einer mehrtägigen Behandlung.

Fetale Wachstumsrestriktion: Ursachen, Risiken und präventive Maßnahmen

Die fetale Wachstumsrestriktion (FGR) stellt ein erhebliches Gesundheitsrisiko für das ungeborene Kind dar und erfordert eine frühzeitige Diagnose. Mütterliche, plazentare und fetale Faktoren spielen eine entscheidende Rolle bei der Entstehung der FGR. Was gilt hier aus Sicht der Behandelnden zu beachten?

Hohe HbA1c-Werte, hohe Prostatakrebsmortalität?

Eine schlechte Blutzuckerkontrolle erhöht zwar nicht die Prostatakrebsinzidenz, möglicherweise aber die Prostatakrebssterblichkeit. Darauf deutet eine Metaanalyse von 13 Studien. Diese hat jedoch erhebliche Schwächen.

EKG Essentials: EKG befunden mit System

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.